Blood-based biomarkers and imaging measures may help monitor MASH disease activity, potentially reducing reliance on liver biopsies. Semaglutide treatment showed significant improvements in liver ...
The American Journal of Managed Care: Noninvasive Tests Show Promise for Tracking Treatment Response in Semaglutide MASH Trial
Noninvasive Tests Show Promise for Tracking Treatment Response in Semaglutide MASH Trial